DSCR 2 Inhibitors
DSCR2 (Down Syndrome Critical Region 2) inhibitors belong to a class of chemical compounds designed to modulate the activity of the DSCR2 protein, primarily by inhibiting or disrupting its function. DSCR2 is a relatively less characterized protein, but it has garnered attention due to its association with genetic factors.
DSCR2 inhibitors typically act by binding to the DSCR2 protein, altering its conformation, or interfering with its interactions with other cellular components. Through these mechanisms, they can inhibit the biological activities of DSCR2, which may include its involvement in cellular processes such as protein-protein interactions, signal transduction, or gene expression regulation. By inhibiting DSCR2, researchers aim to dissect its precise role in cellular pathways and uncover potential connections between DSCR2 dysfunction and molecular pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Binds to cyclophilin and inhibits calcineurin, a phosphatase required for T-cell activation. This prevents the activation of T-cells and suppresses the immune response. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
Forms a complex with FKBP12 and inhibits calcineurin, similar to Cyclosporin A, suppressing T-cell activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Binds to FKBP12 and inhibits mTOR, a kinase involved in cell growth and proliferation, leading to immunosuppression and antiproliferative effects. | ||||||
Mycophenolate mofetil | 128794-94-5 | sc-200971 sc-200971A | 20 mg 100 mg | $37.00 $109.00 | 1 | |
Inhibits inosine monophosphate dehydrogenase (IMPDH), disrupting de novo purine synthesis in lymphocytes and reducing their proliferation. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Blocks dihydroorotate dehydrogenase (DHODH), an enzyme in the pyrimidine synthesis pathway, leading to decreased DNA synthesis and immune cell proliferation. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
Activates S1P receptors on lymphocytes, causing their internalization and reduced egress from lymphoid tissues, thus decreasing immune cell presence in the blood. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Also a JAK inhibitor, primarily targeting JAK1 and JAK2, it modulates cytokine signaling and reduces inflammation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Selectively inhibits JAK1 and JAK2, reducing cytokine-induced inflammation and immune cell activation. | ||||||
Apremilast | 608141-41-9 | sc-480062 | 5 mg | $444.00 | ||
Inhibits phosphodiesterase 4 (PDE4), increasing intracellular levels of cyclic AMP (cAMP), which downregulates inflammatory responses in immune cells. | ||||||